NHS Corby Clinical Commissioning Group
Kettering General Hospital NHS Trust
NHS Nene Clinical Commissioning Group
Northampton General Hospital NHS Trust
Northamptonshire Healthcare NHS Foundation Trust

NORTHAMPTONSHIRE PRESCRIBING ADVISORY GROUP

(Advising Medical, Pharmacy Practitioners and Non-Medical Prescribers on prescribing across the county)

Summary of Recommendations from meeting on Weds 2nd December 2015

- **Vorioxetine (Brintellix®)**
  Vorioxetine is a new antidepressant licensed for major depression in adults. It directly modulates serotonergic receptor activity and inhibits the serotonin (5-HT) transporter. It is a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, a 5-HT1B receptor partial agonist, a 5-HT1A receptor agonist and an inhibitor of the 5-HT transporter; it leads to modulation of neurotransmission in several systems, including predominantly the serotonin but probably also the norepinephrine, dopamine, histamine, acetylcholine, GABA and glutamate systems.
  NICE TA367 advises that vortioxetine is recommended as a possible treatment for adults having a first or recurrent major depressive episode, if the current episode has not responded to 2 antidepressants.
  NPAG categorised vorioxetine as amber 2

- **Avipeptadil/phentolamine intercavernosal injection (Invicorp®)**
  Invicorp is a new intercavernosal injection licensed for the treatment of erectile dysfunction. Aviptadil is a vasoactive intestinal polypeptide and phentolamine is a short-acting alpha-adrenoceptor antagonist. Both drugs cause smooth muscle relaxation of the corpus cavernosa which increases cavernosal artery blood flow, producing an erection.
  NPAG categorised Invicorp as grey, pending an opinion from the urologists at the acute trusts

- **Taptiqom eye drops (tafluprost/timolol)**
  NPAG recategorised Taptiqom eye drops from grey to double red (prior approval) as they are not included in the draft glaucoma formulary currently being finalised.

- **Daylette tablets® (ethinyloestradiol 20mcg and drospirenone 3mg)**
  On the advice of the local family planning consultant**, NPAG categorised Daylette as double red (prior approval)** as it is not perceived to have any advantages over Loestrin and is considerably more expensive. The prior approval criteria would be "on the recommendation of a family planning consultant".

- **Circadin in Parkinson's Disease**
  NPAG approved the use of Circadin for the treatment of insomnia with REM disturbance in patients with Parkinson's Disease, including those under the age of 55 (unlicensed indication).
  NPAG categorised Circadin for insomnia with REM in Parkinson's Disease as amber 2.

- **Ropinirole M/R**
  NPAG re-categorised ropinirole M/R for restless legs' syndrome as amber 2. The M/R preparation remains double red (prior approval) for Parkinson's disease.

- **Stoma Underwear**
  Following consultation with the stoma specialist nurses at NGH and KGH, **NPAG categorised all stoma underwear as double red (IFR).**

- **Shared Care**
  The following shared care guidelines were agreed and will shortly be available on Pathfinder -
  - Low dose aspirin in pregnancy
  - Dronedarone for management of non-permanent atrial fibrillation
  - ADHD in children and adolescents

- **NICE guidance**
  NPAG noted the NICE guidance on the Menopause: Diagnosis and Management
  https://www.nice.org.uk/guidance/ng23
  It was agreed that prescribing of HRT is likely to increase following the release of this guidance.

  The NICE guidance on type 2 diabetes was issued on the same day as the NPAG meeting and will therefore be considered fully at the February meeting. http://www.nice.org.uk/guidance/ng28
  A Patient Decision Aid is available at http://www.nice.org.uk/guidance/ng28/resources/patient-decision-aid-2187281197
  User guide: http://www.nice.org.uk/guidance/ng28/resources/patient-decision-aid-user-guide-2187281198

Further information or clinical trial data may be obtained from the CCG Prescribing Advisers or Hospital Medicines Information Service.